MarketBeat
17 Aug 2026, 01:02 UTC · 3h ago
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
17 Aug 2026, 01:02 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
RenovoRx estimates top-line data from the Phase III TIGeR-PaC study will be available in the second half of 2027. — The long timeline to final data delays the primary catalyst for valuation re-rating and commercial validation.
-0.40The company is targeting potential break-even in the fourth quarter of next year. — A clear path to break-even reduces the immediate risk of dilutive equity raises for a clinical-stage company.
+0.30RenovoRx expanded its active center footprint from four or five last year to 21 centers currently treating patients. — Rapid growth in center adoption indicates strong early clinical interest and scalability of the RenovoCath device.
+0.20Continue reading
6 related stories
Search tags
An interim analysis of the TIGeR-PaC study showed a 65% reduction in toxicities and a trend toward improved survival, though it was not statistically significant. — Positive directional data supports the thesis, but the lack of statistical significance limits immediate market impact.
The company reported $1.5 million in first-half revenue, with $900,000 in the most recent quarter. — While showing growth, the revenue levels are currently immaterial relative to the overall valuation of a med-tech firm.
+0.00Which stocks this story touches
The company reports expanded center adoption, positive interim toxicity data for its TAMP platform, and a path toward break-even.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
1d ago
